MCID: GST030
MIFTS: 44

Gastrinoma

Categories: Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Gastrinoma

MalaCards integrated aliases for Gastrinoma:

Name: Gastrinoma 12 51 41 14 69
Gastrin Secreting Tumor 12
Gastrinoma, Malignant 69
Malignant Gastrinoma 12
Gastrin Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5577
MeSH 41 D015408
NCIt 46 C3050

Summaries for Gastrinoma

Disease Ontology : 12 A neuroendocrine tumor that results_in an overproduction of gastric acid.

MalaCards based summary : Gastrinoma, also known as gastrin secreting tumor, is related to duodenal gastrinoma and pancreatic gastrinoma. An important gene associated with Gastrinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Signaling by GPCR and Gastric acid production. The drugs SecreFlo and Pantoprazole have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and lymph node, and related phenotype is endocrine/exocrine gland.

Related Diseases for Gastrinoma

Diseases related to Gastrinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 duodenal gastrinoma 33.4 GAST MEN1 SCT
2 pancreatic gastrinoma 32.3 CHGA GAST MEN1 SCT SST
3 zollinger-ellison syndrome 32.1 CHGA GAST MEN1 SCT SST
4 duodenitis 31.1 GAST INS
5 multiple endocrine neoplasia 30.8 CHGA MEN1
6 atrophic gastritis 30.0 CHGA GAST
7 pernicious anemia 29.9 GAST SST
8 hyperparathyroidism 29.8 CHGA GAST MEN1
9 ectopic cushing syndrome 29.8 MEN1 SST
10 neuroendocrine tumor 29.7 CHGA GAST MEN1 SST
11 phaeochromocytoma 29.7 CHGA SST
12 multiple endocrine neoplasia, type i 29.7 CHGA GAST INS MEN1 SCT SST
13 pituitary adenoma, prolactin-secreting 29.6 MEN1 SST
14 mixed ductal-endocrine carcinoma 29.5 CHGA GAST SST
15 duodenal ulcer 29.4 GAST INS SCT SST
16 von hippel-lindau syndrome 29.4 CHGA MEN1
17 insulinoma 29.1 CHGA INS MEN1 SCT SST
18 pancreatic islet cell tumors 29.0 GAST INS MEN1 SST
19 glucagonoma 28.9 CHGA SCT SST VIP
20 hyperinsulinemic hypoglycemia, familial, 2 28.5 CHGA GAST INS SCT SST
21 somatostatinoma 28.4 CHGA INS SST VIP
22 islet cell tumor 27.5 CHGA GAST INS MEN1 SST VIP
23 gastric gastrinoma 12.1
24 pancreatitis 10.4
25 hepatitis 10.4
26 diphyllobothriasis 10.3 GAST SCT
27 autoimmune atrophic gastritis 10.3 CHGA GAST
28 goblet cell carcinoid 10.3 CHGA GAST
29 non-functioning pancreatic endocrine tumor 10.3 CHGA GAST
30 pylorospasm 10.3 GAST SST
31 postcholecystectomy syndrome 10.3 GAST SST
32 retinitis pigmentosa 40 10.3 GAST SST
33 tanycytic ependymoma 10.2 CHGA MEN1
34 hyperproinsulinemia 10.2 INS SCT
35 angiodysplasia 10.2 SCT SST
36 pancreatic somatostatinoma 10.2 MEN1 SST
37 hormone producing pituitary cancer 10.2 MEN1 SST
38 adenoma of the pancreas 10.2 CHGA SST
39 steatorrhea 10.2 SCT SST
40 functioning pituitary adenoma 10.2 MEN1 SST
41 pituitary carcinoma 10.2 CHGA SST
42 duodenum cancer 10.2 MEN1 SST
43 pancreatoblastoma 10.2 CHGA SST
44 stomach disease 10.2 GAST SST
45 duodenal somatostatinoma 10.1 INS SST
46 postural hypotension 10.1 INS SST
47 granulosa cell tumor of the ovary 10.1 CHGA INS
48 endocrine organ benign neoplasm 10.1 MEN1 SST
49 hyperpituitarism 10.1 INS SST
50 pituitary tumors 10.1 MEN1 SST

Graphical network of the top 20 diseases related to Gastrinoma:



Diseases related to Gastrinoma

Symptoms & Phenotypes for Gastrinoma

MGI Mouse Phenotypes related to Gastrinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.02 CHGA GAST INS MEN1 VIP

Drugs & Therapeutics for Gastrinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002

Drugs for Gastrinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
2
Lansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3 3883
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 1 138530-94-6, 103577-45-3 9578005
5 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
6 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antacids Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1
11
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
14
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
15
Esomeprazole Approved, Investigational Phase 3,Phase 1 161796-78-7, 119141-88-7 9579578 4594
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
19 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
20 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
22 Antimetabolites Phase 2, Phase 3,Phase 1
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
24 Analgesics Phase 3
25 Central Nervous System Depressants Phase 3
26 Adjuvants, Anesthesia Phase 3
27 Narcotics Phase 3
28 Cinacalcet Hydrochloride Phase 3
29 Analgesics, Opioid Phase 3
30 Anesthetics Phase 3
31 Hormone Antagonists Phase 3,Phase 2,Phase 1
32 Anesthetics, General Phase 3
33 Anesthetics, Intravenous Phase 3
34 Hormones Phase 3,Phase 2,Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
36 Peripheral Nervous System Agents Phase 3
37 Calcimimetic Agents Phase 3
38 Calcium, Dietary Phase 3,Phase 2,Phase 1
39 Folate Nutraceutical Phase 2, Phase 3
40 Vitamin B9 Nutraceutical Phase 2, Phase 3
41 Cola Nutraceutical Phase 3,Phase 1
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
44
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
45
Omeprazole Approved, Investigational, Vet_approved Phase 2,Phase 1 73590-58-6 4594
46
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 54)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
3 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
5 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
6 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
7 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
10 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
11 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
12 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
13 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
14 Effect of G17DT in Patients With Stage II/III Colorectal Cancer Completed NCT02518373 Phase 2 Omeprazole
15 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
16 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
17 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
18 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
19 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
21 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
22 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
23 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
24 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
25 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
26 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
27 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
28 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
29 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
30 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
31 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
32 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
33 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
34 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
35 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
36 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
37 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
38 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
39 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
40 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
41 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
42 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Completed NCT00942175 Phase 1 Clopidogrel;Clopidogrel and Lansoprazole;Clopidogrel and Dexlansoprazole;Clopidogrel and Omeprazole;Clopidogrel and Esomeprazole
43 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
44 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
47 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
48 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
49 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240
50 Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense Completed NCT02278432

Search NIH Clinical Center for Gastrinoma

Cochrane evidence based reviews: gastrinoma

Genetic Tests for Gastrinoma

Anatomical Context for Gastrinoma

MalaCards organs/tissues related to Gastrinoma:

38
Liver, Testes, Lymph Node, Pancreas, Bone, Kidney, Breast

Publications for Gastrinoma

Articles related to Gastrinoma:

(show top 50) (show all 429)
# Title Authors Year
1
Acute kidney injury following vomiting and diarrhea after endoscopy in a duodenal gastrinoma patient. ( 28070096 )
2017
2
Duodenal Gastrinoma Discovered on Evaluation for Incidental Gastric Carcinoid. ( 28300688 )
2017
3
Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 28540972 )
2017
4
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? ( 29019150 )
2017
5
Primary lymph node gastrinoma: A single institution experience. ( 28705492 )
2017
6
A primary hepatic gastrinoma accompanied by hyperplasia of multi-nodular Brunner's glands. ( 29181825 )
2017
7
Gastrinoma ( 28722872 )
2017
8
Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma). ( 28626400 )
2017
9
Disease Control on Lanreotide AutogelAr 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. ( 29430219 )
2017
10
Severe chronic diarrhoea secondary to primary lymph node gastrinoma. ( 28446479 )
2017
11
Medical management of gastrinoma in a cat. ( 28491421 )
2016
12
Clinical treatment of gastrinoma: A case report and review of the literature. ( 27123130 )
2016
13
The Selective Arterial Calcium Injection Test is a Valid Diagnostic Method for Invisible Gastrinoma with Duodenal Ulcer Stenosis: A Case Report. ( 27348901 )
2016
14
(68)Ga-DOTATOC-PET/CT for effective diagnosis and treatment of pancreatic tail gastrinoma with multiple liver metastases: a case report. ( 26743558 )
2016
15
Sporadic, Primary Lymph Node Gastrinoma. ( 27457843 )
2016
16
Metastatic gastrinoma with secretory differentiation to ACTH. ( 27060354 )
2016
17
Synchronous Peripancreatic Lymph Node Gastrinoma and Gastric Neuroendocrine Tumor Type 2. ( 27209642 )
2016
18
Metastatic gastrinoma in the breast mimicking primary solid papillary carcinoma. ( 27342908 )
2016
19
Management of pancreatic gastrinoma associated with Von Hippel-Lindau disease: a case report. ( 27055912 )
2016
20
Impact of a novel 14a88bp MEN1 deletion in a patient with hyperparathyroidism and gastrinoma. ( 26191410 )
2015
21
Laparoscopic-assisted pancreaticoduodenectomy in a child with gastrinoma. ( 26711921 )
2015
22
Primary Hepatic Gastrinoma. ( 26556475 )
2015
23
Intraoperative near-infrared fluorescence visualization of theA duodenal gastrinoma in a patient withA Zollinger-Ellison syndrome. ( 26209566 )
2015
24
Intraoperative Use of a Portable Large Field of View Gamma Camera and Handheld Gamma Detection Probe for Radioguided Localization and Prediction of Complete Surgical Resection of Gastrinoma: Proof of Concept. ( 26206636 )
2015
25
Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. ( 27408649 )
2015
26
Primary jejunal gastrinoma: a case report and review of the literature. ( 26546053 )
2015
27
Primary lymph node gastrinoma: 2 cases and a review of the literature. ( 25623161 )
2015
28
Diagnosis and preoperative tagging of duodenal gastrinoma by endoscopic ultrasound. ( 26492296 )
2015
29
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. ( 25625026 )
2015
30
Surgery for gastrinoma: Short and long-term results. ( 25748044 )
2015
31
An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: an unusual association and review of the literature. ( 25022420 )
2014
32
Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. ( 25003221 )
2014
33
An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. ( 24796622 )
2014
34
Metastatic gastrinoma in a pediatric patient with zollinger-ellison syndrome. ( 23426004 )
2014
35
Misdiagnosed gastrinoma: A case report. ( 24932294 )
2014
36
Case of primary hepatic gastrinoma: Diagnostic usefulness of the selective arterial calcium injection test. ( 25145887 )
2014
37
Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. ( 24961548 )
2014
38
Primary lymph node gastrinoma. A diagnosis of exclusion. A case for duodenotomy in the setting of a negative imaging for primary tumor: A case report and review of the literature. ( 25462049 )
2014
39
Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. ( 22743840 )
2013
40
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. ( 23613167 )
2013
41
Criteria for the glucagon provocative test in the diagnosis of gastrinoma. ( 22983734 )
2013
42
Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. ( 23417896 )
2013
43
Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. ( 22580937 )
2013
44
Primary lymph node gastrinoma: a rare cause of abdominal pain in childhood. ( 23743959 )
2013
45
Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. ( 24363522 )
2013
46
Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 24431117 )
2013
47
Laparoscopic resection for primary lymph node gastrinoma. ( 23591435 )
2013
48
Images of the month: a gastrinoma in the uncinate process of the pancreas. ( 22764021 )
2012
49
Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. ( 23271988 )
2012
50
Primary hepatic gastrinoma causing zollinger-ellison syndrome: a rare and challenging diagnosis. ( 24213231 )
2012

Variations for Gastrinoma

Expression for Gastrinoma

Search GEO for disease gene expression data for Gastrinoma.

Pathways for Gastrinoma

Pathways related to Gastrinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 GAST INS MEN1 NMB SCT SST
2 9.64 GAST SCT VIP

GO Terms for Gastrinoma

Cellular components related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA GAST INS SCT SST
2 extracellular region GO:0005576 9.17 CHGA GAST INS NMB SCT SST

Biological processes related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.43 INS NMB SST
2 G-protein coupled receptor signaling pathway GO:0007186 9.43 GAST INS NMB SCT SST VIP
3 regulation of protein localization GO:0032880 9.32 INS VIP
4 negative regulation of blood vessel diameter GO:0097756 9.16 CHGA INS
5 regulation of receptor activity GO:0010469 9.1 GAST INS NMB SCT SST VIP

Molecular functions related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 GAST INS NMB SCT SST VIP

Sources for Gastrinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....